NTP CHEMICAL REPOSITORY (RADIAN CORPORATION, AUGUST 29, 1991)

HYDROXYUREA




IDENTIFIERS





CATALOG ID NUMBER: 000318

CAS NUMBER: 127-07-1

BASE CHEMICAL NAME: HYDROXYUREA

PRIMARY NAME: HYDROXYUREA

CHEMICAL FORMULA: CH4N2O2

STRUCTURAL FORMULA: HONHCONH2

WLN: ZYQUNQ &421
ZVMQ &422

SYNONYMS:
HYDROXYCARBAMIDE
HYDROXYCARBAMINE
N-(AMINOCARBONYL)HYDROXYLAMINE
N-CARBAMOYLHYDROXYLAMINE
HYDROXYLUREA
CARBAMOHYDROXIMIC ACID
CARBAMOHYDROXAMIC ACID
CARBAMOYL OXIME
CARBAMYL HYDROXAMATE
HU
HYDREA
LITALIR
N-HYDROXYUREA
HYDROXY UREA (D4)
HIDRIX
HYDREIA
LITALER
HYDURA
NCI-C04831
NSC 32065
SQ 1089
BIOSUPRESSIN
CARBAMOHYDROXYAMIC ACID
ONCO-CARBIDE
OXYUREA
SK 22591
HYDUREA
1-HYDROXYUREA
WR 83799





PHYSICAL CHEMICAL DATA





PHYSICAL DESCRIPTION: LITERATURE: White to off-white crystalline powder
REPOSITORY: White crystalline solid

MOLECULAR WEIGHT: 76.07

SPECIFIC GRAVITY: Not available

DENSITY: Not available

MP (DEG C): 144-146 C (decomposes) [275]

BP (DEG C): Decomposes [017,042]

SOLUBILITIES:
WATER : >=100 mg/mL @ 21 C (RAD)

DMSO : 50-100 mg/mL @ 21 C (RAD)

95% ETHANOL : <1 mg/mL @ 21 C (RAD)

METHANOL : Not available

ACETONE : <1 mg/mL @ 21 C (RAD)

TOLUENE : Not available

OTHER SOLVENTS:
Ether: Insoluble [025]
Alcohol: Slightly soluble [295]
Alcohol (hot): Soluble [031,042,205,295]

VOLATILITY:
Vapor pressure: Not available
Vapor density : Not available

FLAMMABILITY(FLASH POINT):
Flash point data for this chemical are not available; however, it is
probably combustible. Fires involving this material can be controlled with
a dry chemical, carbon dioxide or Halon extinguisher.

UEL: Not available LEL: Not available

REACTIVITY: Not available

STABILITY:
This chemical is hygroscopic and decomposes in the presence of moisture
[295]. Solutions of this chemical in water, DMSO, 95% ethanol or acetone
should be stable for 24 hours under normal lab conditions (RAD).

OTHER PHYSICAL DATA:
Odorless or almost odorless [295]
Tasteless [295]





TOXICITY





NIOSH REGISTRY NUMBER: YT4900000

TOXICITY:

       typ. dose    mode     specie      amount     units     other

         TDLo       orl       hmn           80      mg/kg/D

         TDLo       ivn       hmn           86      mg/kg

         LD50       ipr       mus         5800      mg/kg

         TDLo       unr       man          160      mg/kg

         LD10       scu       mus         2400      mg/kg

         LD50       unr       rat         4300      mg/kg


AQTX/TLM96: Not available

SAX TOXICITY EVALUATION:
THR: An experimental teratogen and equivocal tumorigenic agent. In humans,
it has blood effects and unspecified effects. LOW via intraperitoneal
route.

CARCINOGENICITY:
Tumorigenic Data:
TDLo: ipr-rat 2500 mg/kg/7W-I
TDLo: ipr-mus 9750 mg/kg/26W-I
TDLo: scu-mus 500 mg/kg

MUTATION DATA:

      test          lowest dose      |       test          lowest dose

   -----------   -----------------   |   ------------   -----------------

   dnd-esc          100 mmol/L       |   mmo-clr             5 mmol/L

   dni-esc          100 mmol/L       |   dni-nml:emb        20 mmol/L

   pic-esc            1 mmol/L       |   oms-nml:emb        20 mmol/L

   oms-bcs           10 mmol/L       |   dni-hmn-orl        50 mg/kg/10H-C

   mrc-omi           75 mmol/L       |   dni-hmn-unr        25 mg/kg

   dnd-omi          250 mg/L         |   oms-hmn:oth         1 mmol/L

   dni-omi           10 mmol/L       |   dni-hmn:oth         1 mmol/L

   cyt-omi           10 mmol/L       |   dns-hmn:fbr        10 mmol/L

   oms-omi           75 mmol/L       |   cyt-hmn:hla         1 mmol/L

   dni-smc           75 mmol/L       |   cyt-hmn:leu       333 umol/L/48H

   oms-mus:lym       20 mg/L         |   dni-hmn:oth        10 mmol/L

   dni-hmn:bmr        1 mmol/L       |   dni-hmn:lym       360 umol/L

   dni-hmn:hla        1 umol/L/4H    |   dni-hmn:fbr      1300 umol/L

   oms-hmn:lym       12 nmol/L       |   dni-hmn:hla        60 mg/L

   dni-mus-ivg        1 pph          |   dni-mus:lym       200 umol/L

   dni-hmn:oth       50 mg/L         |   oms-hmn:oth        50 mg/L

   oms-hmn:lym       80 mg/L         |   oms-hmn:hla        60 mg/L

   dni-omi          500 mg/L         |   dni-omi            75 mmol/L

   oms-hmn:oth       50 mg/L         |   dnd-rat-ipr       500 mg/kg

   dns-rat-ipr      300 mg/kg/8H     |   dns-rat:lvr        10 mmol/L

   dni-rat-ipr        3 ug/kg/2H-I   |   cyt-ham:ovr       300 umol/L

   dni-rat:lvr        1 mmol/L       |   mnt-mus-ipr       400 mg/kg

   otr-mus:emb       10 umol/L       |   dnd-mus/mmr       200 mg/kg

   dnd-mus:emb       40 mg/L         |   dns-mus-ipr         6 gm/kg

   dns-mus:leu      100 umol/L       |   dni-mus:kdy         1 mmol/L

   dni-mus:mmr        5 mmol/L       |   dni-mus:leu        10 mmol/L

   dni-mus:spr        1 mmol/L/1H-C  |   dni-mus:fbr         2 mmol/L

   dni-mus-ipr      100 mg/kg        |   oms-mus/mmr       200 mg/kg

   dni-mus:oth        1 mmol/L       |   cyt-mus-ipr        20 mg/kg

   cyt-mus:emb       50 umol/L       |   spm-mus-ipr       125 mg/kg/5D

   dni-ham:ovr      100 mg/L         |   dni-ham:fbr        10 ug/L

   dni-ham:lng      200 umol/L       |   dni-ham:kdy        13 umol/L

   dni-ham:emb        1 mmol/L       |   cyt-ham:lng       500 ug/L

   cyt-ham:oth       50 umol/L       |   sce-ham:fbr       100 umol/L

   dni-gpg:oth        5 mmol/L/30M-C |   dni-gpg:kdy         1 mmol/L

   dnd-mam:oth      100 umol/L       |   dnd-omi            50 mg/L

   cyt-mus:lym        1 mmol/L       |   dni-hmn:oth         5 mmol/L

   dni-rat-par     1500 mg/kg/3D-C   |   dns-hmn:oth         5 mmol/L

   mrc-smc         7600 mg/L         |   mmo-smc          7600 mg/L

   mma-ham:lng       20 mmol/L       |   mma-sat             1 mg/plate

   sce-mus:lym        1 mmol/L       |   sln-smc          7600 mg/L

   dni-hmn:oth        1 mmol/L       |   dnr-esc           250 ug/well

   msc-mus:lym       10 mg/L         |   sce-ham:ovr         1 mmol/L


TERATOGENICITY:
Reproductive Effects Data:
TDLo: ipr-dog 150 mg/kg (21D preg)
TDLo: ipr-dog 450 mg/kg (20-22D preg)
TDLo: ipr-dog 450 mg/kg (21-23D preg)
TDLo: ipr-ham 50 mg/kg (5D male)
TDLo: ipr-mus 250 mg/kg (11D preg)
TDLo: ipr-mus 7 mg/kg (1D male)
TDLo: ipr-mus 800 mg/kg (11D preg)
TDLo: ipr-mus 300 mg/kg (9D preg)
TDLo: ipr-mus 500 mg/kg (10D preg)
TDLo: ipr-pig 450 mg/kg (14-16D preg)
TDLo: ipr-rat 1 gm/kg (12 preg)
TDLo: ipr-rat 250 mg/kg (9D preg)
TDLo: ipr-rat 200 mg/kg (9-12D preg)
TDLo: ivn-ham 50 mg/kg (8D preg)
TDLo: ivn-ham 400 mg/kg (8D preg)
TDLo: ivn-mus 500 mg/kg (10D preg)
TDLo: orl-cat 100 mg/kg (13-14D preg)
TDLo: orl-cat 1300 mg/kg (10-22D preg)
TDLo: orl-mus 2500 mg/kg (8-12D preg)
TDLo: orl-rat 2800 mg/kg (7-20D preg)
TDLo: orl-rat 3 gm/kg (6-15D preg)
TDLo: orl-rat 4500 mg/kg (6-15D preg)
TDLo: par-rat 150 mg/kg (9D preg)
TDLo: par-rat 1800 mg/kg (15D preg)
TDLo: scu-rat 650 mg/kg (12D preg)
TDLo: scu-rbt 650 mg/kg (12D preg)
TDLo: scu-rbt 750 mg/kg (12D preg)
TDLo: unr-mus 500 mg/kg (10D preg)
TDLo: unr-rat 500 mg/kg (12D preg)
TDLo: unr-rat 350 mg/kg (6D preg)
TDLo: unr-rat 2500 ug/kg (12D preg)

STANDARDS, REGULATIONS & RECOMMENDATIONS:
OSHA: None
ACGIH: None
NIOSH Criteria Document: None
NFPA Hazard Rating: Health (H): None
Flammability (F): None
Reactivity (R): None

OTHER TOXICITY DATA:
Skin and Eye Irritation Data:
skn-hmn 218 mg/3W
Review: Toxicology Review-3
Status: Meets criteria for proposed OSHA Medical Records Rule
EPA TSCA Test Submission (TSCATS) Data Base, March 1988
EPA Genetox Program 1986, Inconclusive: Carcinogenicity-mouse/rat;
Mammalian micronucleus
EPA Genetox Program 1986, Positive: Cell transform.-SA7/SHE
EPA Genetox Program 1986, Positive: In vitro cytogenetics-human
lymphocyte
EPA Genetox Program 1986, Positive: E coli polA without S9; sperm
morphology-mouse
EPA Genetox Program 1986, Positive: S cerevisiae gene conversion
EPA Genetox Program 1986, Negative: Cell transform.-BALB/c-3T3;
In vitro SCE-nonhuman
EPA Genetox Program 1986, Negative: V79 cell culture-gene mutation





OTHER DATA (Regulatory)





PROPER SHIPPING NAME (IATA): Not restricted

UN/ID NUMBER:

HAZARD CLASS: SUBSIDIARY RISK: PACKING GROUP:

LABELS REQUIRED:

PACKAGING: PASSENGER: PKG. INSTR.: MAXIMUM QUANTITY:
CARGO : PKG. INSTR.: MAXIMUM QUANTITY:

SPECIAL PROVISIONS:

USES:
This compound is an antineoplastic agent and immunosuppressant. It
is used in the treatment of chronic myeloid leukemia, malignant melanomas
and inoperable tumors of the ovary, and squamous cell carcinomas of the
head and neck (with radiotherapy).

COMMENTS:
This compound is an inhibitor of DNA synthesis [275].





HANDLING PROCEDURES





ACUTE/CHRONIC HAZARDS:
When heated to decomposition this compound emits toxic fumes of NOx [042].

MINIMUM PROTECTIVE CLOTHING: Not available

RECOMMENDED GLOVE MATERIALS:
Permeation Test Results For The Neat (Undiluted) Chemical:
The permeation test results for the neat (undiluted) chemical are given
below. The breakthrough times of this chemical are given for each glove type
tested. The table is a presentation of actual test results, not specific
recommendations or suggestions. Avoid glove types which exhibit breakthrough
times of less than the anticipated task time plus an adequate safety factor.
If this chemical makes direct contact with your glove, or if a tear, puncture
or hole develops, replace them at once.

Glove Type Model Number Thickness Breakthrough Time
No information available

RECOMMENDED RESPIRATOR:
Where the neat test chemical is weighed and diluted, wear a NIOSH-
approved half face respirator equipped with an organic vapor/acid gas
cartridge (specific for organic vapors, HCl, acid gas and SO2) with a
dust/mist filter.

OTHER: Not available

STORAGE PRECAUTIONS:
You should store this chemical under refrigerated temperatures,
and protect it from moisture.

SPILLS AND LEAKAGE:
If you spill this chemical, you should dampen the solid spill material
with water, then transfer the dampened material to a suitable container. Use
absorbent paper dampened with water to pick up any remaining material. Seal
your contaminated clothing and the absorbent paper in a vapor-tight plastic
bag for eventual disposal. Wash all contaminated surfaces with a soap
and water solution. Do not reenter the contaminated area until the Safety
Officer (or other responsible person) has verified that the area has been
properly cleaned.

DISPOSAL AND WASTE TREATMENT: Not available





EMERGENCY PROCEDURES





SKIN CONTACT:
IMMEDIATELY flood affected skin with water while removing and isolating
all contaminated clothing. Gently wash all affected skin areas thoroughly
with soap and water.
If symptoms such as redness or irritation develop, IMMEDIATELY call a
physician and be prepared to transport the victim to a hospital for treatment.

INHALATION:
IMMEDIATELY leave the contaminated area; take deep breaths of fresh air.
If symptoms (such as wheezing, coughing, shortness of breath, or burning in
the mouth, throat, or chest) develop, call a physician and be prepared to
transport the victim to a hospital.
Provide proper respiratory protection to rescuers entering an unknown
atmosphere. Whenever possible, Self-Contained Breathing Apparatus (SCBA)
should be used; if not available, use a level of protection greater than or
equal to that advised under Respirator Recommendation.

EYE CONTACT:
First check the victim for contact lenses and remove if present. Flush
victim's eyes with water or normal saline solution for 20 to 30 minutes while
simultaneously calling a hospital or poison control center.
Do not put any ointments, oils, or medication in the victim's eyes without
specific instructions from a physician.
IMMEDIATELY transport the victim after flushing eyes to a hospital even if
no symptoms (such as redness or irritation) develop.

INGESTION:
DO NOT INDUCE VOMITING. If the victim is conscious and not convulsing,
give 1 or 2 glasses of water to dilute the chemical and IMMEDIATELY call a
hospital or poison control center. Be prepared to transport the victim to a
hospital if advised by a physician.
If the victim is convulsing or unconscious, do not give anything by mouth,
ensure that the victim's airway is open and lay the victim on his/her side with
the head lower than the body. DO NOT INDUCE VOMITING. IMMEDIATELY transport
the victim to a hospital.

SYMPTOMS:
Symptoms of exposure to this compound include bone marrow suppression
including megaloblastic changes, pulmonary edema and neurological reactions
such as headache and dizziness [295]. Other neurological reactions include
drowsiness, disorientation, hallucinations and convulsions. Impairment of
renal function may occur [295,301]. Other symptoms include megaloblastic
anemia, leukopenia, thrombocytopenia, gastrointestinal disturbances, mild
dermatological reactions, stomatitis and alopecia [406]. Exposure may also
cause maculopapular rash, facial erythema, dysuria and fever [301].
Symptoms of exposure to this type of compound include anorexia, nausea,
vomiting, allergic reactions including skin rashes, erythema and pruritus,
hypotension, malaise, weakness, anaphylaxis, vesication or irritation of the
skin and mucous membranes and possible thrombophlebitis (when injected) [295].
Prolonged exposure to this type of compound may cause bone marrow depres-
sion, anemia, bleeding, immunosuppression, mouth ulcers, esophagitis, abdom-
inal pain, hemorrhage, diarrhea, intestinal ulceration and perforation, hyper-
uricemia, acute renal failure due to uric acid nephropathy, hyperphosphatemia,
pigmentaion of the skin and nails and jaundice [295].





SOURCES





SOURCES:
[015] Lewis, R.J., Sr. and R.L. Tatken, Eds. Registry of Toxic Effects
of Chemical Substances. Microfiche Ed. National Institute for
Occupational Safety and Health. Cincinnati, OH. Quarterly
Updates. YT4900000.

[017] Weast, R.C., M.J. Astle, and W.H. Beyer, Eds. CRC Handbook of
Chemistry and Physics. 67th Ed. CRC Press, Inc. Boca Raton,
FL. 1986. p. C-540, #14745.

[025] Buckingham, J., Ed. Dictionary of Organic Compounds. 5th Ed.
Chapman and Hall. New York. 1982. Vol. 3, p. 3263, #H-03539.

[031] Windholz, M., Ed. The Merck Index. 10th Ed. Merck and Co.
Rahway, NJ. 1983. p. 708, #4772.

[042] Sax, N.I. Dangerous Properties of Industrial Materials. 6th Ed.
Van Nostrand Reinhold. New York. 1984. pp. 1600-1601.

[047] Weast, R.C. and M.J. Astle, Eds. CRC Handbook of Data on
Organic Compounds. CRC Press, Inc. Boca Raton, FL.
1985. Vol. II, p. 418, #U00195.

[052] Midwest Research Institute. MRI Report for Hydroxyurea.
Kansas City, MO. July 10, 1978.

[082] U.S. Environmental Protection Agency, Office of Toxic Substances.
Toxic Substances Control Act Chemical Substance Inventory: 1985
Edition. 5 Vols. U.S. Environmental Protection Agency.
Washington, D.C. January 1986. Not listed.

[110] Oak Ridge National Laboratory. Environmental Mutagen Information
Center (EMIC), Bibliographic Data Base. Oak Ridge National
Laboratory. Oak Ridge, TN. Not listed.

[120] Oak Ridge National Laboratory. Environmental Teratogen Information
Center (ETIC), Bibliographic Data Base. Oak Ridge National
Laboratory. Oak Ridge, TN. Listed.

[159] Huff, B.B., Ed. Physicians' Desk Reference. 41st Ed. Medical
Economics Co. Oradell, NJ. 1987. p. 1950.

[205] Dean, John A., Ed. Lange's Handbook of Chemistry. 13th Ed.
McGraw-Hill Book Company. New York. 1985. p. 7-459, #h397.

[275] Aldrich Chemical Company. Aldrich Catalog/Handbook of Fine
Chemical. Aldrich Chemical Co., Inc. Milwaukee, WI.
1988. p. 864, #11,520-7.

[295] Reynolds, James E.F., Ed. Martindale The Extra Pharmacopoeia. 28th Ed.
The Pharmaceutical Press. London. 1982. p. 212.

[301] Dreisbach, R.H. Handbook of Poisoning: Prevention, Diagnosis
and Treatment. 11th Ed. Lange Medical Publications. Los
Altos, CA. 1983. p. 498.

[406] Goodman, L.S., A. Gilman, F. Murad and T.W. Rall, Eds. The
Pharmacological Basis of Therapeutics. 7th Ed. Macmillan
Publishing Co. New York. 1985. pp. 1291-1292.

[610] Clansky, Kenneth B., Ed. Suspect Chemicals Sourcebook: A Guide to
Industrial Chemicals Covered Under Major Federal Regulatory and
Advisory Programs. Roytech Publications, Inc. Burlingame, CA.
1990. Section 3, p. 55.

[620] United States National Toxicology Program. Chemical Status Report.
NTP Chemtrack System. Research Triangle Park, NC. November 6, 1990.
Not listed.

-------------------------------------------------------------